Results 31 to 40 of about 4,891,805 (263)

MRI findings in juvenile Huntington's disease

Radiology Case Reports, 2021
Juvenile Huntington's disease is a rare neurodegenerative disorder that first affects the basal ganglia. Presented here is a case of juvenile Huntington's disease in an 8-year-old male. Clinical features included epilepsy and developmental delay. Imaging
Patrick Arraj, BS, Kyle Robbins, BS, Lauren Dengle Sanchez, MD, Daniel L. Veltkamp, MD, Cory M. Pfeifer, MD, MPH   +4 more
doaj   +1 more source

Mutant Huntingtin Does Not Affect the Intrinsic Phenotype of Human Huntington's Disease T Lymphocytes.

PLoS ONE, 2015
Huntington's disease is a fatal neurodegenerative condition caused by a CAG repeat expansion in the huntingtin gene. The peripheral innate immune system is dysregulated in Huntington's disease and may contribute to its pathogenesis.
James R C Miller, Ulrike Träger, Ralph Andre, Sarah J Tabrizi   +3 more
doaj   +1 more source

Longitudinal study of informed consent in innovative therapy research: experience and provisional recommendations from a multicenter trial of intracerebral grafting. [PDF]

PLoS ONE, 2015
There is an urgent need to assess and improve the consent process in clinical trials of innovative therapies for neurodegenerative disorders.We performed a longitudinal study of the consent of Huntington's disease patients during the Multicenter Fetal ...
Laurent Cleret de Langavant, Sophie Sudraud, Christophe Verny, Pierre Krystkowiak, Clémence Simonin, Philippe Damier, Jean-François Demonet, Frédéric Supiot, Amandine Rialland, David Schmitz, Patrick Maison, Katia Youssov, Anne-Catherine Bachoud-Lévi   +12 more
doaj   +1 more source

Short-interval observational data to inform clinical trial design in Huntington's disease. [PDF]

, 2015
OBJECTIVES: To evaluate candidate outcomes for disease-modifying trials in Huntington's disease (HD) over 6-month, 9-month and 15-month intervals, across multiple domains.
Roos, Raymund AC, Cole, James H, Sprengelmeyer, R, Cole, JH, Mueller, H.P., Malone, IB, Hobbs, Nicola Z., Durr, Alexandra, Johnson, H., Mueller, Hans-Peter, Roos, R.A.C., Scahill, R.I., Sprengelmeyer, Reiner, Haider, Salman, Frost, C, Hobbs, Nicola Z, Hobbs, N.Z., Farmer, RE, Farmer, R.E., Tabrizi, S.J., Cole, James H.; id_orcid, Durr, A, Tabrizi, SJ, Johnson, H, Sussmuth, S.D., Tabrizi, Sarah J., Farmer, Ruth E, Rees, Elin M, Scahill, Rachael I, Hobbs, NZ, Haider, S., Frost, Chris, Farmer, Ruth E., Mueller, Hans Peter, Landwehrmeyer, B., Cole, James H., Sprengelmeyer, R., Sussmuth, Sigurd D., Malone, Ian B, Malone, I.B., Landwehrmeyer, B, Durr, A., Rees, Elin M., Roos, RA, Scahill, Rachael I., Malone, Ian B., Rees, EM, Landwehrmeyer, Bernhard, Tabrizi, Sarah J, Frost, C., Sussmuth, Sigurd D, Mueller, HP, Scahill, RI, Sussmuth, SD, Cole, J.H., Roos, Raymund A.C., Sprengelmeyer, Reiner Heinrich, Haider, S, Johnson, Hans, Rees, E.M.   +59 more
core   +1 more source

Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease. [PDF]

, 2012
BACKGROUND: Deterioration of cognitive functioning is a debilitating symptom in many neurodegenerative diseases, such as Huntington's disease (HD). To date, there are no effective treatments for the cognitive problems associated with HD.
Stout, J.C., Justo, D., Labuschagne, Izelle, Langbehn, D.R., Hart, Ellen P, Labuschagne, I., Stout, Julie C, Frost, Chris, Leavitt, Blair R, Dürr, Alexandra, Santos, R.D., Jones, Rebecca, Hart, E.P., O'Regan, A.M., Santos, Rachelle Dar, Say, Miranda J, Durr, A., Dumas, Eve M, Roos, R.A., Dumas, E.M., Queller, Sarah, Tabrizi, Sarah J, Frost, C., Say, M.J., Coleman, A., Tabrizi, S.J., Justo, Damian, Roos, Raymund A, Leavitt, B.R., O'Regan, Alison M, Coleman, Allison, Langbehn, Doug R, Queller, S., Jones, R.   +33 more
core   +1 more source

Avoidance as a strategy of (not) coping: qualitative interviews with carers of Huntington's Disease patients [PDF]

, 2005
Peer ...
Lowit, Alison, van Teijlingen, Edwin R.
core   +4 more sources

In silico designing of putative peptides for targeting pathological protein Htt in Huntington's disease

Heliyon, 2021
Huntington's disease is a neurodegenerative disease caused by CAG repeat in the first exon of HTT (Huntingtin) gene, leading to abnormal form of Htt protein containing enlarged polyglutamine strands of variable length that stick together to form ...
Harleen Kohli, Pravir Kumar, Rashmi K. Ambasta   +2 more
doaj   +1 more source

Novel methods and therapeutic approaches of diagnosis and treatment of Huntington's disease [PDF]

, 2008
Huntington’s Disease is a neurodegenerative disorder characterized by motor dysfunction, emotional disturbance, dementia and weight loss. The disorder is caused by an autosomal dominant expansion of a CAG repeat encoding for a polyglutamine stretch in ...
Weiss, Andreas
core   +1 more source

Silencing Huntington's chorea: Is RNA Interference a Potential Cure? [PDF]

Impulse: The Premier Undergraduate Neuroscience Journal, 2006
In 1872, George Huntington described Huntington's disease as characterized by motor, cognitive and psychiatric impairments. Huntington's disease is a dominant and autosomal mutation on chromosome 4 featuring the insertion of numerous CAG repeats.
Gerlinde A. Metz, Ian Q. Whishaw, Afra Foroud, Nafisa M. Jadavji   +3 more
doaj  

Disease stage, but not sex, predicts depression and psychological distress in Huntington's disease. A European population study

, 2016
Objective: Depression and anxiety significantly affect morbidity in Huntington's disease. Mice.models of Huntington's disease have identified sex differences in mood-like behaviours that vary across disease lifespan, but this interaction has not ...
Shimozaki, Steve, Maltby, John, REGISTRY Investigators of the European Huntington's Disease Network, Cramp, Rebecca, Romano, Silvia., Dale, Maria, Rickards, Hugh   +6 more
core   +1 more source